These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
215 related items for PubMed ID: 23110887
41. Quantitative MRI-pathology correlations of brain white matter lesions developing in a non-human primate model of multiple sclerosis. Blezer EL, Bauer J, Brok HP, Nicolay K, 't Hart BA. NMR Biomed; 2007 Apr; 20(2):90-103. PubMed ID: 16948176 [Abstract] [Full Text] [Related]
42. Personalized pathology maps to quantify diffuse and focal brain damage. Bonnier G, Fischi-Gomez E, Roche A, Hilbert T, Kober T, Krueger G, Granziera C. Neuroimage Clin; 2019 Apr; 21():101607. PubMed ID: 30502080 [Abstract] [Full Text] [Related]
50. High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Schmierer K, Parkes HG, So PW, An SF, Brandner S, Ordidge RJ, Yousry TA, Miller DH. Brain; 2010 Mar; 133(Pt 3):858-67. PubMed ID: 20123726 [Abstract] [Full Text] [Related]
51. Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI. Zheng Y, Dudman J, Chen JT, Mahajan KR, Herman D, Fox RJ, Ontaneda D, Trapp BD, Nakamura K. Mult Scler; 2022 Feb; 28(2):198-205. PubMed ID: 34014144 [Abstract] [Full Text] [Related]
53. Imaging outcomes for trials of remyelination in multiple sclerosis. Mallik S, Samson RS, Wheeler-Kingshott CA, Miller DH. J Neurol Neurosurg Psychiatry; 2014 Dec; 85(12):1396-404. PubMed ID: 24769473 [Abstract] [Full Text] [Related]
54. Remyelination varies between and within lesions in multiple sclerosis following bexarotene. Brown JWL, Prados F, Altmann DR, Kanber B, Stutters J, Cunniffe NG, Jones JL, Georgieva ZG, Needham EJ, Daruwalla C, Wheeler-Kingshott CG, Connick P, Chandran S, Franklin R, MacManus D, Samson R, Coles A, Chard D. Ann Clin Transl Neurol; 2022 Oct; 9(10):1626-1642. PubMed ID: 36116011 [Abstract] [Full Text] [Related]
55. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging. Enzinger C, Strasser-Fuchs S, Ropele S, Kapeller P, Kleinert R, Fazekas F. Mult Scler; 2005 Apr; 11(2):135-9. PubMed ID: 15794384 [Abstract] [Full Text] [Related]
56. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. Dousset V, Brochet B, Vital A, Gross C, Benazzouz A, Boullerne A, Bidabe AM, Gin AM, Caille JM. AJNR Am J Neuroradiol; 1995 Feb; 16(2):225-31. PubMed ID: 7726066 [Abstract] [Full Text] [Related]
57. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. Arnold DL, Wolinsky JS, Matthews PM, Falini A. J Neurol Neurosurg Psychiatry; 1998 May; 64 Suppl 1():S94-101. PubMed ID: 9647294 [Abstract] [Full Text] [Related]
59. Magnetization Transfer MRI of Breast Cancer in the Community Setting: Reproducibility and Preliminary Results in Neoadjuvant Therapy. Virostko J, Sorace AG, Wu C, Ekrut D, Jarrett AM, Upadhyaya RM, Avery S, Patt D, Goodgame B, Yankeelov TE. Tomography; 2019 Mar; 5(1):44-52. PubMed ID: 30854441 [Abstract] [Full Text] [Related]
60. Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. Zivadinov R, Hussein S, Bergsland N, Minagar A, Dwyer MG. Front Biosci (Elite Ed); 2012 Jan 01; 4(4):1496-504. PubMed ID: 22201970 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]